Nordihydroguaiaretic acid, 97%

pyruvate-dehydrogenase inhibitor

Product Name :
Nordihydroguaiaretic acid, 97%

Synonym:

IUPAC Name :
4-[(2R,3S)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol

CAS NO.:
500-38-9

Molecular Weight :

Molecular formula:
C18H22O4

Smiles:
C[C@@H](CC1=CC=C(O)C(O)=C1)[C@H](C)CC1=CC=C(O)C(O)=C1

Description:
Nordihydroguaiaretic acid is used in the treatment of multiple diseases, including cardiovascular diseases, neurological disorders and cancers.Etrasimod It is also used as an antioxidant.Ajudecunoid A PMID:24140575

Related Posts

The mechanism under burn wound healing is a complicated network quite different from that in other types of wound such as incision, laceration or chronic ulcer with little tissue loss or interference with blood supply

The system underneath burn up wound therapeutic is a complicated network really diverse from that in other types of wound this sort of as incision, laceration or chronic ulcer with tiny tissue loss or interference with blood provide. The human body could be compromised when skin was progressively dropped and blood source was not PX105684 […]

Ent subjects. HUVEC data are means ?SEM of five replicates at

Ent subjects. HUVEC data are means ?SEM of five replicates at each concentration. (C) Combining D and Q selectively reduced viability of both senescent preadipocytes and senescent HUVECs. Proliferating and senescent preadipocytes and HUVECs were exposed to a fixed concentration of Q and different concentrations of D for 3 days. Optimal Q concentrations for inducing […]

Imilar scores for the three predictors. (TIF) Figure S8 Kaplan-Meier overall

Imilar scores for the three predictors. (TIF) Figure S8 Kaplan-Meier overall survival stratification between COXEN-matched and unmatched patients in the TCGA-448 cohort. (A) all patients (B) platinum-sensitive patients, (C) platinum-resistant patients. (TIF) Figure S9 Kaplan-Meier progression-free survival stratification between COXEN-matched and unmatched patients in the TCGA-448 cohort. (A) all patients (B) platinum-sensitive patients, (C) platinum-resistant […]